BCL2 and non-small cell lung carcinoma: According to the PASS predictions, prodigiosin had a high probability (Pa > 0.5) of exhibiting various anticancer activities, including an apoptosis agonist (Pa = 0.723), antineoplastic (non-small cell lung cancer, Pa = 0.549; solid tumors, Pa = 0.428; and others), and bcl2 antagonist (Pa = 0.310).